Regenerative Medicine
FDA Approves Humacyte’s Symvess ATEV: A Breakthrough in Regenerative Medicine for Vascular Trauma Treatment
Humacyte, FDA approval, Symvess ATEV, regenerative medicine, vascular trauma, lab-grown blood vessels
Aurion Biotech’s AURN001 Shows Significant Vision Improvement in Phase 1/2 Trial for Corneal Edema
AURN001, corneal edema, corneal endothelial dysfunction, allogeneic cell therapy, regenerative medicine, clinical trial results
uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130
uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)
Astellas Expands Cell Therapy Research with New Japan Site for Universal Cells
Astellas, Universal Cells, cell therapy, regenerative medicine, Japan research site, allogeneic cell therapy
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
uniQure, Huntington’s disease, AMT-130, gene therapy, Phase I/II trials, disease progression, neurofilament light protein (NfL), Unified Huntington’s Disease Rating Scale (cUHDRS), Regenerative Medicine Advanced Therapy (RMAT) designation